✦ LIBER ✦

Erratum: Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial

✍ Scribed by CRN Rasch; M Hauptmann; J Schornagel; O Wijers; J Buter; T Gregor; R Wiggenraad; JP de Boer; AH Ackerstaff; R Kroger; FJP Hoebers; AJM Balm

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 59 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25234

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intra-arterial versus intravenous chemor

Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial

✍ Coen R. N. Rasch; Michael Hauptmann; Jan Schornagel; Oda Wijers; Jan Buter; Theo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB 👁 1 views

Alternating chemoradiotherapy versus par

Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck : Results from a phase III randomized trial

✍ Renzo Corvò; Marco Benasso; Giuseppe Sanguineti; Rita Lionetto; Almalina Bacigal 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 1 views

## BACKGROUND. The authors previously have found that in patients with locally advanced squamous cell carcinoma of the head and neck (SCC-HN), alternating chemoradiotherapy (ALT) was superior to low-total-dose conventional radiotherapy alone. The purpose of this randomized trial was to compare the

Taxane-based chemoirradiation for organ

Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: Results of a phase II multi-institutional trial

✍ Anthony J. Cmelak; Barbara A. Murphy; Brian Burkey; Stacy Douglas; Yu Shyr; Jame 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 1 views

## Abstract ## Background. The optimal drug schedule and sequencing of chemotherapy and radiation for organ preservation in head and neck cancer has yet to be determined. We undertook a phase II trial of a taxane‐based induction chemotherapy (ICT) followed by a taxane‐based concurrent chemoradiati